miércoles, 29 de julio de 2020

Immunizations Information Systems (IIS) Vaccine Code Set Release Notes 7/28/2020


Release Date of 7/28/2020

Release notes: This release does not include updates for Vaccine Information Statement (VIS) codes and maps. Release notes and files for VIS code updates are distributed in separate release cycles.
General Note regarding this release: Codes with “Last Update” dates after May 8, 2020 and before July 23, 2020 reflect the changes and additions in this release. It includes the following code set updates:

  1. CVX Code Additions and Updates:
    CVX Code Additions: Three new CVX codes have been added

Table 1: New Active CVX Codes
CVX CodeFull Vaccine NameStatusNotes
205
influenza, seasonal vaccine, quadrivalent, adjuvanted, .5mL dose, preservative free
Active
Supports new vaccine influenza product in this release for the 2020/2021 season.  See CPT code updates
203
meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine .5mL dose, preservative free
Active
Supports new vaccine product in this release.  See CPT code updates
206
smallpox monkeypox vaccine, live attenuated, preservative free (National Stockpile
Active
National Stockpile product CVX added at request of Military Health.  Note that the CDC vaccine code set does not support all stockpile products.  No CPT code assigned.

CVX Code Updates:  Two CVX codes have been updated

Table 2: CVX Code Status and Description Changes
CVX CodeFull Vaccine NameStatusNotes
62
human papilloma virus vaccine, quadrivalent

Active


Status changed from Inactive to Active.  The status for this CVX was changed to Inactive in error in 2015 when the new Gardasil 9 product was introduced and CVX code 165 added for the 9-valent HPV vaccine.  Active NDCs for the Gardasil quadrivalent product are still included as active on the FDA files and DailyMed.  These active NDCs remain mapped to CVX 65.
194
influenza, Southern Hemisphere, unspecified formulation

Inactive


This CVX code previously had a status of Non-US.  This status has been changed to inactive and the description now indicates that this should be used for any administration where the formulation is unknown.  There are now active US NDCs mapped to active CVX codes for the Southern Hemisphere influenza.  Consistent with other unspecified formulation CVX codes, the status is now shown as “Inactive”.  It can be used to document a past vaccine administration where the specific product formulation is not known.
197

influenza, high-dose seasonal, quadrivalent, .7mL dose, preservative free
Active

Description changed to identify dose volume that reflects the high-dose vaccine presentation.  See CPT code updates.

  1. Product Tradename Updates: Three new product tradenames have been added

    Table 3: New Vaccine Products
Product TradenameManufacturerMVX CodeCVX CodeCVX Description
FLUAD QuadrivalentSeqirus
SEQ
205
Influenza vaccine, quadrivalent, adjuvanted
JYNNEOSBavarian Nordic A/S
BN
206
Smallpox monkeypox vaccine (National Stockpile)
MenQuadfiSanofi Pasteur
PMC
203
meningococcal polysaccharide (groups A, C, Y, W-135) TT conjugate

  1. CPT Code to CVX Mapping Updates: Two CPT to CVX Code maps have been updated
Table 4: CPT to CVX Mapping Updates
CPT CodeCPT DescriptionCVX CodeCVX Short DescriptionComment
90662
Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use
197
influenza, high-dose, quadrivalentCPT 90662 is now mapped to both CVX 135 and newly mapped to CVX Code 197.  CVX code 197 supports the new FLUZONE High-Dose Quadrivalent product from Sanofi.  Although the CPT does not reference that it is quadrivalent, the manufacturer has advised its customers to use this CPT.  CPT 90662 has historically been mapped to CVX 135, Influenza, high dose seasonal, for past season high-dose influenza vaccines (not quadrivalent). All products applicable to CVX code 135 are now retired. To maintain history, we have kept the mapping of CPT 90662 to CVX 135. We will update the mapping if a new CPT that is a better match for CVX code 197 is made available.
90694
Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use
205
Influenza vaccine, quadrivalent, adjuvantedCPT code 90694 mapping has been changed from the less specific CVX 150, influenza, injectable, quadrivalent, preservative free, to the new CVX code 205 which supports the new FLUAD Quadrivalent product for the 2020/2021 Season and more accurately reflects this CPT code.
150
influenza, injectable, quadrivalent, preservative free,Mapping of CPT code 90694 to CVX code 150 has been removed.  It should be noted that the mapping of CPT code 90686 to CVX 150 continues to remain in effect.
90619
Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use
203
meningococcal polysaccharide (groups A, C, Y, W-135) TT conjugateCPT code mapped to new CVX code (related to new MenQuadfi product)

  1. NDC Unit of Sale and Unit of Use Code Updates:
    2020/2021 Seasonal Flu Vaccines:  Table 5 below lists the 2020/2021 influenza season vaccines that are new (N), and the associated 2019/2020 seasonal vaccines that have been retired (R)

    Table 5: Seasonal Influenza NDCs
Sale Proprietary NameN=New
R=Ret
Sale NDC11Use NDC11Sale LabelerCVXMVX
Afluria Quadrivalent
N
33332-0220-20
33332-0220-21
Seqirus Pty Ltd.
161
SEQ
R
33332-0219-20
33332-0219-21
Seqirus Pty Ltd.
161
SEQ
Afluria Quadrivalent
N
33332-0320-01
33332-0320-02
Seqirus Pty Ltd.
150
SEQ
R
33332-0319-01
33332-0319-02
Seqirus Pty Ltd.
150
SEQ
Afluria Quadrivalent
N
33332-0420-10
33332-0420-11
Seqirus Pty Ltd.
158
SEQ
R
33332-0419-10
33332-0419-11
Seqirus Pty Ltd.
158
SEQ
FLUAD
N
70461-0020-03
70461-0020-04
Seqirus Inc.
168
SEQ
70461-0019-03
70461-0019-04(*)
Seqirus Inc.
168
SEQ
FLUAD Quadrivalent (1)
N
70461-0120-03
70461-0120-04
Seqirus Inc.
205
SEQ
R
N/A
N/A
N/A
N/A
N/A
FLUARIX QUADRIVALENT
N
58160-0885-52
58160-0885-41
GlaxoSmithKline Biologicals SA
150
SKB
R
58160-0896-52
58160-0896-41
GlaxoSmithKline Biologicals SA
150
SKB
Flublok Quadrivalent
N
49281-0720-10
49281-0720-88
Sanofi Pasteur Inc.
185
PMC
R
49281-0719-10
49281-0719-88
Sanofi Pasteur Inc.
185
PMC
FLUCELVAX QUADRIVALENT
N
70461-0420-10
70461-0420-11
Seqirus Inc.
186
SEQ
R
70461-0419-10
70461-0419-11
Seqirus Inc.
186
SEQ
FLUCELVAX QUADRIVALENT
N
70461-0320-03
70461-0320-04
Seqirus Inc.
171
SEQ
R
70461-0319-03
70461-0319-04
Seqirus Inc.
171
SEQ
Flulaval Quadrivalent
N
19515-0816-52
19515-0816-41
ID Biomedical Corporation of Quebec
150
IDB
R
19515-0906-52
19515-0906-41
ID Biomedical Corporation of Quebec
150
IDB
Flulaval Quadrivalent  (2)
N
N/A
N/A
N/A
N/A
N/A
R
19515-0897-11
19515-0897-01
ID Biomedical Corporation of Quebec
158
IDB
FLUZONE High-Dose (3)
N
N/A
N/A
N/A

PMC
R
49281-0405-65
49281-0405-88
 Sanofi Pasteur Inc.
135
 PMC
FLUZONE High-Dose Quadrivalent (4)
N
49281-0120-65
49281-0120-88
Sanofi Pasteur Inc.
197
PMC
R
N/A
N/A
N/A
N/A
N/A

Notes for Table 5
(1) FLUAD Quadrivalent is a new product for the 2020/2021 season
(2) Flulaval Quadrivalent multi-dose product has not been provided as this point for the 2020/2021 season.
(3) FLUZONE High-Dose (not quadrivalent) has been retired, an no new NDCs provided at this point
(4) FLUZONE High-Dose Quadrivalent is a new product for the 2020/2021 season.  It was added to the vaccine code set as a new product in late 2019, but is listed here to provide an inclusive list of all the new 2020/2021 vaccine NDCs identified to date
(*)  FLUAD NDC 70461-0019-04 is listed above as retired, but the end date is not yet updated in this release
The following non-influenza vaccines have been added:
Table 6: New Vaccine NDC
Sale Proprietary NameN=New
R=Retired
Sale NDC11Use NDC11Sale LabelerCVXMVX
MenQuadfi (1)
N
49281-0590-0549281-0590-58
Sanofi Pasteur Inc.
203
PMC
R
NA
NA

(1) MenQuadfi is a new product.  The NDC Start Date for MenQuadfi is 4/23/2020 – this date is also the effective date for the new related CVX code and the product/tradename associations.

No hay comentarios:

Publicar un comentario